00:34 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million on Oct. 17 in a round led by existing investor New Enterprise Associates (NEA). New investor...
22:58 , Oct 17, 2017 |  BC Extra  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million in a round led by existing investor New Enterprise Associates (NEA). New investor Longitude Capital and...
23:00 , Jun 30, 2017 |  BC Extra  |  Company News

Management tracks

Cell therapy play BlueRock Therapeutics (Toronto, Ontario) named Emile Nuwaysir president and CEO, and Robert Deans chief technology officer. Nuwaysir was president and COO at Cellular Dynamics International Inc. , which Fujifilm Holdings Corp. (Tokyo:4901)...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Buying American

Even though OrbiMed Advisors just scored a massive win with Dutch cancer company Acerta Pharma B.V. , the firm's new $950 million venture fund is unlikely to be active in Europe. "We've essentially stopped raising...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Cardioxyl, Bristol-Myers deal

Bristol-Myers Squibb completed its acquisition of cardiovascular company Cardioxyl (see BioCentury, Nov. 9). Cardioxyl Pharmaceuticals Inc. , Chapel Hill, N.C.   Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.   Business: Cardiovascular  ...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Cardioxyl, Bristol-Myers deal

Bristol-Myers Squibb will acquire cardiovascular company Cardioxyl for $300 million in combined upfront and near-term milestone payments and up to $1.8 billion in development, regulatory and sales milestones. Cardioxyl is developing lead candidate CXL-1427 ,...
01:15 , Nov 3, 2015 |  BC Extra  |  Company News

BMS acquires Cardioxyl

Bristol-Myers Squibb Co. (NYSE:BMY) will acquire Cardioxyl Pharmaceuticals Inc. (Chapel Hill, N.C.), which is developing cardiovascular therapies including lead candidate CXL-1427 . The second-generation prodrug of nitroxyl (HNO) is in a Phase II study to...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

True North Therapeutics Inc management update

True North Therapeutics Inc ., South San Francisco, Calif.   Business: Hematology, Renal, Neurology   Hired: James Gilbert as CMO, a newly created position, formerly CMO of Cardioxyl Pharmaceuticals Inc.  ...
00:50 , Jun 18, 2014 |  BC Extra  |  Financial News

True North closes $22 million A round

True North Therapeutics Inc. (South San Francisco, Calif.) raised an undisclosed amount in a tranched $22 million series A round. Kleiner Perkins Caulfield & Byers; MPM Capital; SR One; Biogen Idec New Ventures; and Baxter...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

CXL-1427: Phase I started

Cardioxyl began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate ascending doses of 24- and 48-hour infusions of IV CXL-1427, starting at a 0.1 µg/kg/min dose, in up to 110 healthy volunteers. Cardioxyl Pharmaceuticals...